L R Pasquale1, J H Kang. 1. Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Brigham and Women's Hospital, Harvard Medical School, 243 Charles Street, Boston, MA 02114, USA. Louis_Pasquale@meei.harvard.edu
Abstract
PURPOSE: The purpose of this study was to explore the relation between age at menarche, parity, and oral contraceptive (OC) use, and primary open-angle glaucoma (POAG). METHODS: We followed 79 440 women in the Nurses' Health Study prospectively from 1980 to 2006 and identified 813 cases of incident POAG. Eligible participants were ≥40 years old, free of POAG at baseline, had information on reproductive history, and reported receiving eye examinations during follow-up. Relevant exposure data and POAG risk factors were updated using biennial questionnaires. We used proportional hazards models to calculate multivariable rate ratios (MVRRs) of POAG and 95% confidence intervals (CI). RESULTS: In multivariable analysis, there were no significant linear trends between age at menarche (P for trend=0.65) or reproductive duration defined as time between age at menarche and menopause (P for trend=0.30) and POAG. Although ever using OCs was not associated with POAG risk (MVRR=1.14; 95% CI, 0.98, 1.34), ≥5 years of OC use was associated with a modest 25% increased risk of POAG (MVRR=1.25; 95% CI, 1.02, 1.53; P for linear trend=0.04). Furthermore, among past OC users, a shorter time since stopping OC use was also associated with an increased risk of POAG (P for linear trend=0.02). Parity was not associated with POAG risk. CONCLUSION: The ≥5 years of OC use was associated with a modestly increased risk of POAG. These data add further support for a role of circulating estrogen in the pathogenesis of POAG.
PURPOSE: The purpose of this study was to explore the relation between age at menarche, parity, and oral contraceptive (OC) use, and primary open-angle glaucoma (POAG). METHODS: We followed 79 440 women in the Nurses' Health Study prospectively from 1980 to 2006 and identified 813 cases of incident POAG. Eligible participants were ≥40 years old, free of POAG at baseline, had information on reproductive history, and reported receiving eye examinations during follow-up. Relevant exposure data and POAG risk factors were updated using biennial questionnaires. We used proportional hazards models to calculate multivariable rate ratios (MVRRs) of POAG and 95% confidence intervals (CI). RESULTS: In multivariable analysis, there were no significant linear trends between age at menarche (P for trend=0.65) or reproductive duration defined as time between age at menarche and menopause (P for trend=0.30) and POAG. Although ever using OCs was not associated with POAG risk (MVRR=1.14; 95% CI, 0.98, 1.34), ≥5 years of OC use was associated with a modest 25% increased risk of POAG (MVRR=1.25; 95% CI, 1.02, 1.53; P for linear trend=0.04). Furthermore, among past OC users, a shorter time since stopping OC use was also associated with an increased risk of POAG (P for linear trend=0.02). Parity was not associated with POAG risk. CONCLUSION: The ≥5 years of OC use was associated with a modestly increased risk of POAG. These data add further support for a role of circulating estrogen in the pathogenesis of POAG.
Authors: C A Hulsman; I C Westendorp; R S Ramrattan; R C Wolfs; J C Witteman; J R Vingerling; A Hofman; P T de Jong Journal: Am J Epidemiol Date: 2001-07-15 Impact factor: 4.897
Authors: Wee-Shian Chan; Joel Ray; Eugene K Wai; Shiphra Ginsburg; Shiphira Ginsburg; Mary E Hannah; Paul N Corey; Jeffrey S Ginsberg Journal: Arch Intern Med Date: 2004-04-12
Authors: Janey L Wiggs; Jae Hee Kang; Brian L Yaspan; Daniel B Mirel; Cathy Laurie; Andrew Crenshaw; Wendy Brodeur; Stephanie Gogarten; Lana M Olson; Wael Abdrabou; Elizabeth DelBono; Stephanie Loomis; Jonathan L Haines; Louis R Pasquale Journal: Hum Mol Genet Date: 2011-08-26 Impact factor: 6.150
Authors: Hassan Hashemi; Mehdi Khabazkhoob; Mohammad Hassan Emamian; Mohammad Shariati; Abbasali Yekta; Akbar Fotouhi Journal: Int J Ophthalmol Date: 2016-08-18 Impact factor: 1.779
Authors: Donald L Budenz; Keith Barton; Julia Whiteside-de Vos; Joyce Schiffman; Jagadeesh Bandi; Winifred Nolan; Leon Herndon; Hanna Kim; Graham Hay-Smith; James M Tielsch Journal: JAMA Ophthalmol Date: 2013-05 Impact factor: 7.389
Authors: Thasarat S Vajaranant; Brandon R Grossardt; Pauline M Maki; Louis R Pasquale; Arthur J Sit; Lynne T Shuster; Walter A Rocca Journal: Menopause Date: 2014-04 Impact factor: 2.953